Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of troxerutin in preparing medicine resisting viral hepatitis

A viral hepatitis and viral technology, applied in the direction of antiviral agents, pharmaceutical formulations, organic active ingredients, etc., can solve the problems of no drug treatment, lack of specific pathological animal models, etc., to increase selectivity and facilitate a wide range of The effect of easy use and availability of raw materials

Inactive Publication Date: 2010-05-19
上海双科医药科技有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathological mechanism and drug research of hepatitis C are one of the research hotspots, but there is still a lack of specific pathological animal models, and there is no ideal drug for clinical treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of troxerutin in preparing medicine resisting viral hepatitis
  • Application of troxerutin in preparing medicine resisting viral hepatitis
  • Application of troxerutin in preparing medicine resisting viral hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 In vitro anti-hepatitis B virus test of troxerutin

[0022] 1. Materials and Methods

[0023] 1.1 Cell culture and drugs

[0024] Using HepG2 2.2.15 cells as a model, inoculate HepG2 2.2.15 cells to 25cm 2 In the culture flask, add 5ml of DMEM medium mixed culture solution (containing 10% FBS and 380μg / ml G418) to each bottle, place at 37°C, 5% CO 2 Passaging in a constant temperature incubator for 3 to 4 days. with 5% NaHCO 3 Adjust the pH to 7.2. (DMEM medium and fetal bovine serum are products of GIBCO; G418 is a product of Sigma).

[0025] Adefovir dipivoxil (product of Suzhou GlaxoSmithKline Pharmaceutical Co., Ltd.), dissolved in dimethyl sulfoxide to make a 1 mg / ml solution, was diluted to 5 μg / ml with culture medium.

[0026] Troxerutin (product of Shaanxi Senfu Biotechnology Co., Ltd.), dissolved in dimethyl sulfoxide to make a 1 mg / ml solution, was diluted with culture medium to 1 μg / ml, 2.5 μg / ml, and 5 μg / ml respectively. solution.

[0027]...

Embodiment 2

[0045] Example 2 In vivo anti-hepatitis B virus test of troxerutin

[0046] 1. Experimental materials:

[0047] 1.1 virus

[0048] Duck hepatitis B virus DNA (DHBV-DNA) strongly positive serum was collected from Shanghai shelduck and stored at -70°C.

[0049] 1.2 Animals

[0050] 1-day-old Peking duck (product of the animal farm of the Institute of Medicine and Plants, Beijing Academy of Medical Sciences).

[0051] 1.3 Drugs

[0052] Adefovir dipivoxil (product of Suzhou GlaxoSmithKline Pharmaceutical Co., Ltd., China); Troxerutin (product of Shaanxi Senfu Biotechnology Co., Ltd.). The above drugs were made into liposomes of 1 mg / ml respectively, diluted with water for injection and then administered.

[0053] 1.4 Reagent α-32 P-dCTP (product of Beijing Furui Company); gap translation kit (product of Promega Company); SephadexG-50, Ficoll PVP (product of Pharmacia, Sweden); SDS (product of Merck, Germany); Protist DNA, bovine serum albumin (product of Institute of Biophy...

Embodiment 3

[0070] Example 3 Experiment of the hepatoprotective effect of troxerutin on the immune liver injury model in mice induced by bacillus Calmette-Guerin (BCG) and lipopolysaccharide (LPS)

[0071] 1. Experimental materials

[0072] 1.1 Experimental animals

[0073] Kunming mice, ♂, 18-22g (product of Experimental Animal Center of Second Military Medical University).

[0074] 1.2 Drugs and reagents

[0075] Troxerutin (product of Shanxi Senfu Biotechnology Co., Ltd.) was made into 1 mg / ml liposome, diluted with water and administered by injection.

[0076] Ribavirin injection (product of Shanghai Xinyi Pharmaceutical Co., Ltd.).

[0077] Bacillus Calmette-Guerin (BCG) (product of Shanghai Biological Products Company).

[0078] Lipopolysaccharide (LPS) (product of Sigma).

[0079] ALT, AST kit (product of Nanjing Jiancheng Institute of Bioengineering)

[0080] 2. Experimental methods and results

[0081] Animals were divided into random groups, tail ivBCG2Sit / only, the norma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel application of troxerutin in a medicine. By carrying out in-vitro and in-vivo pharmacological experiments of resisting hepatitis B viruses and hepatitis C viruses on the troxerutin, a result proves that the troxerutin has an obvious function of suppressing the hepatitis B viruses and the hepatitis C viruses. Therefore, the troxerutin can be used for preparing a medicine resisting viral hepatitis, especially for preparing a medicine resisting viral hepatitis B and viral hepatitis C. Moreover, the price of the required raw materials is low, the raw materials are easy to obtain, and the use in a large range is convenient.

Description

technical field [0001] The present invention relates to the application of Troxerutin in medicine; in particular, it relates to the new application of Troxerutin in the preparation of antiviral hepatitis drugs, especially the new application in the preparation of antiviral hepatitis B and viral hepatitis C drugs use. Background technique [0002] Viral hepatitis B is a common disease that seriously endangers human health. Its prevention and treatment is a global public health problem, which has attracted the attention of governments all over the world. my country is a high-incidence area of ​​viral hepatitis, with an average incidence rate of 120-140 / 100,000. Among them, hepatitis B is the most prominent. Hepatitis B is a worldwide disease caused by the hepatitis B virus. The incidence rate is high in developing countries. According to statistics, there are more than 280 million asymptomatic hepatitis B virus carriers in the world, and my country accounts for about 93 mil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P31/20A61P31/12
Inventor 徐从立黄山
Owner 上海双科医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com